Abstracts tagged "Clinical Response and ethics"

Abstract Number: 2413 • 2014 ACR/ARHP Annual Meeting
Similar Response Rates to Anti-Tumor Necrosis Factor and Non- Anti-Tumor Necrosis Factor Biologic Therapies in Ethnic Minority Patients at 6 Months
Gail S. Kerr¹, Yusuf Yazici², Christopher Swearingen³, Luis R. Espinoza⁴, Edward L. Treadwell⁵, Yvonne Sherrer⁶, Angelia Mosley-WIlliams⁷, Ignacio Garcia-Valladares⁸, Rodolfo Perez Alamino⁹, Sharon Dowell¹⁰, Mercedes Quinones¹¹, Akgun Ince¹², Theresa Lawrence Ford¹³, Chunqiao Luo¹⁴, Adrian Godoy¹⁰ and John Amatruda¹⁵, ¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Pediatrics and Biostatistics, University of Arkansas, Little Rock, AR, ⁴Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA, ⁵Dept Medicine Div of Rheum, East Carolina University, Greenville, NC, ⁶Rheum/Immunology, Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, ⁷Rheumatology, Detroit VAMC, Detroit, MI, ⁸Immunology and Rheumatology, Hospital General de Occidente, Zapopan, Jal., Mexico, ⁹internal Medicine, LSUHSC, New Orleans, LA, ¹⁰Division of Rheumatology, Howard University, Washington, DC, ¹¹Division of Rheumatology, Howard University Hospital, Washington, DC, ¹²Arthitis Consultants Inc, St. Louis University, St. Louis, MO, ¹³North Georgia Rheumatology Group, PC, Lawrenceville, GA, ¹⁴University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁵Rheumatology, Howard University, Washington, DC
Similar Response Rates to Anti-Tumor Necrosis Factor and Non- Anti-Tumor Necrosis Factor Biologic Therapies in Ethnic Minority Patients Background/Purpose: Biologic therapies have expanded the treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].